Compare Citius Pharmaceuticals Inc (CTXR) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.61. The key difference: Vanguard Sht-Term Inflation-Protected Sec Idx ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | VTIP | |
|---|---|---|
Market Cap | $14.64M | — |
Sector | Health | — |
52-Week High | $1.82 | $50.75 |
52-Week Low | $0.53 | $49.39 |
Enterprise Value | $10.86M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
VTIP trades at $49.61, down slightly by 0.06% with a bearish technical signal from moving averages. The ETF focuses on short-term inflation-protected securities, offering investors protection against persistent inflation currently running at 3.8%. Recent institutional activity shows mixed positioning with several firms increasing holdings while others trimmed positions. The overall technical picture remains cautious despite neutral oscillator readings.
VTIP provides inflation hedging with potential 3.8% returns in the current environment, though the Fed's reluctance to cut rates in 2026 presents headwinds. The ETF's short-term TIPS focus reduces duration risk but remains sensitive to inflation expectations and monetary policy shifts. Key risks include interest rate volatility and inflation trajectory uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
